Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Retinoids are crucial signaling molecules with therapeutic applications.
• Developing novel retinoids with improved efficacy and safety is an ongoing challenge.
• Heteroarotinoids, a novel class of retinoids, were synthesized for evaluation.

Purpose of the Study:

• To synthesize and evaluate the biological activity of novel heteroarotinoids.
• To assess their potential as chemotherapeutic agents.
• To determine their in vivo toxicity and therapeutic ratio.

Main Methods:

• Synthesis of heteroarotinoids containing heteroatoms in a cyclic ring.
• In vitro assays using human cell lines (GMO6141A, CC-1, CC-B) to measure differentiation, apoptosis, and proliferation.
• Reporter gene assays to determine retinoic acid receptor activation.
• In vivo toxicity studies in mice (B6D2F1) using gavage administration.

Main Results:

• Heteroarotinoids demonstrated dose-responsive activity in differentiation, apoptosis, and proliferation assays.
• Strong correlations were observed between RARE transactivation, TGase induction, and growth inhibition.
• In vivo studies showed that heteroarotinoids have target organs consistent with trans-retinoic acid (t-RA) toxicity.
• Compounds 8 and 10 exhibited significantly reduced toxicity (3000-fold less than TTNPB) while retaining substantial biological activity.

Conclusions:

• Heteroarotinoids possess significant chemotherapeutic potential due to their ability to induce differentiation, inhibit proliferation, and activate nuclear receptors.
• The synthesized heteroarotinoids exhibit a favorable therapeutic ratio, with markedly reduced toxicity compared to TTNPB.
• These findings support the further development of heteroarotinoids as novel anticancer agents.